Navigation Links
Researcher develops screening tool to identify patients with prediabetes
Date:12/4/2008

COLUMBIA, Mo. A third of Americans with diabetes do not know that they have it, and many more who have prediabetic conditions are unaware that they are at risk. A University of Missouri researcher has created a clinical tool to identify those at highest risk for having undetected hyperglycemia, impaired fasting glucose (IFG) and undiagnosed diabetes. If these conditions are identified early, patients may benefit from preventative strategies that can minimize progression to diabetes, other diseases and mortality.

"Diabetic risk factors are not equal and assessing a combination of risk factors can be confusing," said Richelle J. Koopman, assistant professor of family and community medicine in the MU School of Medicine. "A tool that weighs the relative contributions of multiple risk factors and creates an overall risk score will help clinicians decide which patients to screen for diabetes. The tool we have developed is easy to use and the screening can be done with pencil and paper. Patients can do it at a health fair or a physician's office."

The Tool to Assess Likelihood of Fasting Glucose Impairment (TAG-IT) is designed to use factors that are self-reported or easily measured. The six factors include: age, sex, BMI, family history resting heart rate and measured high blood pressure.

The average age of diagnosis for diabetes in the United States is 46 years old. However, patients are likely to develop prediabetic conditions at a younger age. In the United States, 57 million people have IFG. As type 2 diabetes becomes an increasing burden in younger populations, it's important to have a screening tool that can assess undiagnosed diabetes and IFG in people as young as 20, Koopman said.

"There has been increasing evidence that prediabetic states are associated with diseases and other complications, and strategies that prevent diabetes in those with prediabetes are effective," Koopman said. "The TAG-IT tool will help phy
'/>"/>

Contact: Kelsey Jackson
JacksonKN@missouri.edu
573-882-8353
University of Missouri-Columbia
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. LA BioMed researchers among Southern California Super Doctors
2. Researchers discover new enzyme in cancer growth
3. Researchers identify cell group key to Lyme disease arthritis
4. Interferon needed for cells to remember how to defeat a virus, UT Southwestern researchers report
5. MU researcher calls for increase in sexual assault awareness programs on college campuses
6. VisEn Co-Founder Named Radiologic Societys Outstanding Researcher of the Year
7. Children Tell Researchers: Well Get Fit if Its Fun
8. Researchers identify how binge drinking may drive heart disease
9. UCSD researchers identify potential new drug target for chronic leukemia
10. USC researchers identify novel approach for suppressing prostate cancer development
11. Researchers identify new leprosy bacterium
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researcher develops screening tool to identify patients with prediabetes
Researcher develops screening tool to identify patients with prediabetes
Breaking Medicine News(10 mins):Health News:Moravia Worldwide to Present Live Webinar on Creation and Use of Terminology in Localization 2Health News:Moravia Worldwide to Present Live Webinar on Creation and Use of Terminology in Localization 3Health News:Lung Cancer Alliance Praises Growing National Coalition 2Health News:Lung Cancer Alliance Praises Growing National Coalition 3Health News:Book Offers Help for Parents Struggling with Difficult Teens During the Upcoming Holidays 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:Procter & Gamble Announces Appointment of Director 2
Breaking Medicine Technology:Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 1Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 2Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 3Study Finds Racial Inequalities Cost U S Health System Over 2450 Billion a Year 57473 4Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 1Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 2Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 3Cowen Healthcare Royalty Partners Establishes Strategic Advisory Board 14117 4Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 1Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 2Intarcia Therapeutics Inc Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes 14115 3
Other Medicine Technology:Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 4Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 5Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 2Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 3Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 4Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 5Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 6Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium 7